# Phase 2 hypertension trials recruiting: 80 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 80 trials in phase 2 for hypertension that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 hypertension trials: 80 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 3 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/hypertension

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 80
- Recruiting or not yet: 80
- Read on: November 19, 2026

## Trials

The 25 newest of 80, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07933328 | Study to Evaluate ALN-CIDEB in Adults With Fibrotic Alcohol-Associated Liver Disease (ALD) | Regeneron Pharmaceuticals | Phase 2 | Not yet recruiting | Alcohol-Associated Liver Disease, ALD | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07933328) |
| November 6, 2026 | NCT07923591 | Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic... | United Therapeutics | Phase 2 | Not yet recruiting | Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923591) |
| November 3, 2026 | NCT07913074 | A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye Drops in Adults With... | Tavo Biotherapeutics | Phase 2 | Recruiting | Primary Open - Angle Glaucoma (POAG), Ocular Hypertension (OHT) | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07913074) |
| October 30, 2026 | NCT07907757 | Colchicine in Pulmonary Artery Hypertension Patients | Ain Shams University | Phase 2 | Not yet recruiting | Pulmonary Hypertension | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07907757) |
| October 26, 2026 | NCT07895966 | Phase IIA Study of Belzutifan in EPAS1-, EGLN1-, or VHL-Mutant Erythrocytosis | University of Utah | Phase 2 | Not yet recruiting | Erythrocytosis, Pulmonary Hypertension, Thrombosis | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895966) |
| September 29, 2026 | NCT07847710 | Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion... | The First Affiliated Hospital with Nanjing Medical University | Phase 2 | Recruiting | Intrahepatic Cholangiocarcinoma (Icc), Neoadjuvant Therapy | 81 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07847710) |
| September 23, 2026 | NCT07835984 | A Study to Evaluate Efficacy and Safety of GW906 Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by One or... | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 2 | Not yet recruiting | Hypertension | 560 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07835984) |
| September 22, 2026 | NCT07833098 | A Phase II Study of VB19055 in Uncontrolled or Resistant Hypertension | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | Phase 2 | Not yet recruiting | Hypertension, Resistant Hypertension, Uncontrolled Hypertension | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07833098) |
| September 15, 2026 | NCT07821398 | Hyperpolarized Xenon MRI in Adults With Pulmonary Hypertension in Interstitial Lung Disease and Systemic Sclerosis | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Interstitial Lung Disease, Pulmonary Hypertension, Systemic Sclerosis | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07821398) |
| August 28, 2026 | NCT07793253 | Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 | Not yet recruiting | Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc), Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma... | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07793253) |
| August 25, 2026 | NCT07783802 | A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event | Eli Lilly and Company | Phase 2 | Recruiting | Atherosclerosis, Cardiovascular Disease, Obesity, Hypertension, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783802) |
| August 12, 2026 | NCT07761572 | CS1 Added to Standard of Care Therapy for Pulmonary Arterial Hypertension | Cereno Scientific AB | Phase 2 | Not yet recruiting | Pulmonary Arterial Hypertension | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07761572) |
| July 30, 2026 | NCT07737522 | Myocardial Metabolic Flux in Pulmonary Arterial Hypertension | Imperial College London | Phase 2 | Not yet recruiting | Pulmonary Arterial Hypertension | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07737522) |
| June 17, 2026 | NCT07654140 | A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Uncontrolled Hypertension | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 2 | Recruiting | Uncontrolled Hypertension | 252 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07654140) |
| June 15, 2026 | NCT07648251 | Furosemide vs Placebo in Severe Preeclampsia Postpartum | Universidad Nacional Autonoma de Honduras | Phase 2 | Not yet recruiting | Severe Preeclampsia | 186 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07648251) |
| June 15, 2026 | NCT07647003 | A Study to Evaluate the Effect of Two Fixed-Dose Leucine, Sildenafil and Metformin Combinations on Blood Pressure in Individuals With... | NuSirt Biopharma | Phase 2 | Not yet recruiting | Hypertension | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07647003) |
| June 15, 2026 | NCT07646860 | A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032) | Merck Sharp & Dohme LLC | Phase 2 | Recruiting | Pulmonary Arterial Hypertension | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07646860) |
| June 12, 2026 | NCT07645300 | LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD Trial | VA Office of Research and Development | Phase 2 | Not yet recruiting | Hypertension Treated With Antihypertensive Drugs, Chronic Kidney Disease, 3B and 4 | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07645300) |
| May 29, 2026 | NCT07614438 | Effect of Vasopressin Versus Norepinephrine on Post-operative Mean Pulmonary Arterial Pressure Following Pulmonary Endarterectomy Surgery, | Fondation Hôpital Saint-Joseph | Phase 2 | Not yet recruiting | Anesthesia, Pulmonary Hypertension, Chronic Pulmonary Thromboembolism, Vasopressor | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07614438) |
| May 27, 2026 | NCT07610278 | A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant... | Novartis Pharmaceuticals | Phase 2 | Recruiting | Hypercholesterolaemia | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07610278) |
| May 22, 2026 | NCT07602166 | Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans | Vanderbilt University Medical Center | Phase 2 | Recruiting | Salt Sensitivity of Blood Pressure, High Blood Pressure, Inflammation, Renin-Angiotensin-Aldosterone System | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07602166) |
| May 22, 2026 | NCT07601295 | Tiprelestat Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH) | Stanford University | Phase 2 | Not yet recruiting | Pulmonary Arterial Hypertension (PAH) | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07601295) |
| April 28, 2026 | NCT07553442 | A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran | Alnylam Pharmaceuticals | Phase 2 | Recruiting | Hypertension | 93 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07553442) |
| April 21, 2026 | NCT07543120 | An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients. | Novartis Pharmaceuticals | Phase 2 | Recruiting | Hypertension (HTN) | 323 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07543120) |
| April 6, 2026 | NCT07511361 | Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe... | Kardigan, Inc. | Phase 2 | Recruiting | Hypertension, Acute Severe Hypertension, Hypertensive Emergency, Hypertensive Urgency | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07511361) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Vanderbilt University Medical Center | 3 |
| Shanghai Zhongshan Hospital | 2 |
| Emory University | 2 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 2 |
| National Cancer Institute (NCI) | 2 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 2 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 2 |
| Massachusetts General Hospital | 2 |
| University of Utah | 2 |
| Tianjin Medical University Cancer Institute and Hospital | 2 |
| VA Office of Research and Development | 2 |
| [Shenzhen Salubris Pharmaceuticals Co., Ltd.](https://specstream.ai/data/clinical-trials/company/shenzhen-salubris-pharmaceuticals-co-ltd) | 2 |
| Pulmovant, Inc. | 1 |
| University of Alberta | 1 |
| AllRock Bio, Inc. | 1 |
| University Hospital Pilsen | 1 |
| Harbin Medical University | 1 |
| [Shin Poong Pharmaceutical Co. Ltd.](https://specstream.ai/data/clinical-trials/company/shin-poong-pharmaceutical-co-ltd) | 1 |
| Ain Shams University | 1 |
| [United Therapeutics](https://specstream.ai/data/clinical-trials/company/united-therapeutics) | 1 |
| Kardigan, Inc. | 1 |
| Cereno Scientific AB | 1 |
| King Edward Medical University | 1 |
| University of Southern California | 1 |
| Imperial College London | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 41 |
| China | 15 |
| France | 6 |
| Poland | 4 |
| Spain | 4 |
| South Korea | 4 |
| Japan | 4 |
| Australia | 3 |
| Germany | 3 |
| United Kingdom | 3 |
| Netherlands | 3 |
| Canada | 2 |
| Latvia | 2 |
| Italy | 1 |
| Belgium | 1 |
| Czechia | 1 |
| Croatia | 1 |
| Pakistan | 1 |
| Colombia | 1 |
| Israel | 1 |
| South Africa | 1 |
| Turkey (Türkiye) | 1 |
| Singapore | 1 |
| Honduras | 1 |
| Argentina | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Machine shops in the United States](https://specstream.ai/data/businesses/machine-shops/united-states)
- [Animation studios in the United States](https://specstream.ai/data/businesses/animation-studios/united-states)
- [HVAC suppliers in the United States](https://specstream.ai/data/businesses/hvac-suppliers/united-states)
- [Ukrainian restaurants in the United States](https://specstream.ai/data/businesses/ukrainian-restaurants/united-states)
- [Flooring contractors in the United States](https://specstream.ai/data/businesses/flooring-contractors/united-states)
- [Software development companies in the United States](https://specstream.ai/data/businesses/software-development-companies/united-states)
